Please provide your email address to receive an email when new articles are posted on . Most patients who qualify for an SGLT2 inhibitor are not prescribed one. Prescription rates for those with a ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...

Please provide your email address to receive an email when new articles are posted on . Treatment with sodium-glucose cotransporter-2 inhibitors for type 2 diabetes may reduce the risk for rheumatoid ...

GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...

STOCKHOLM -- The sodium glucose co-transporter 2 (SGLT2) class of diabetes medications may offer more protection against diabetic retinopathy as compared with other hypoglycemic agents, an analysis of ...

HOUSTON -- SGLT2 inhibitors may hold a benefit for a wider pool of patients with chronic kidney disease (CKD) than previously thought, a pair of meta-analyses indicated. SGLT2 inhibitors helped to ...

Patients prescribed SGLT2 inhibitors less likely to exhibit nodule growth and to undergo a surgical intervention. HealthDay News — For patients with diabetes and early-stage pulmonary malignancies, ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. The primary outcome was ...

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among patients with pulmonary arterial hypertension (PAH), according to an ...

A large population-based study found that adults with type 2 diabetes (T2D) who start treatment with sodium–glucose ...